J Korean Med Sci.  2012 Jul;27(7):827-829. 10.3346/jkms.2012.27.7.827.

Suspected Anaphylactic Reaction Associated with Microemulsion Propofol during Anesthesia Induction

• Lee SJ
• Kim SI
• Jung BI
• Lee SM
• Kim MG
• Park SY
• Kim SH
• Ok SY

• KMID: 2157933
• DOI: http://doi.org/10.3346/jkms.2012.27.7.827

Abstract

Although rare, intraoperative anaphylaxis can lead to significant morbidity and mortality. Aquafol(R) (Daewon Pharmaceutical Co. Ltd., Seoul, Korea), a microemulsion propofol, was developed to eliminate lipid solvent-related adverse events, and was used in clinical anesthesia since 2009 with little data about severe side effects such as anaphylaxis. A healthy 16-yr-old male patient who had past medical history with two previous operations of no complications developed cardiovascular shock with generalized erythema following administration of microemulsion propofol during anesthesia induction. Intravenous injection of epinephrine and steroid rescued him. He remained in a stable state without any problems postoperatively and was discharged. Clinicians should consider this rare but serious complication during induction of anesthesia with propofol.

Keyword

Anaphylactic Reaction; Anesthetics; Aquafol; Complications; Microemulsion Propofol

MeSH Terms

Adolescent
Anaphylaxis/*chemically induced/drug therapy
Anesthetics, Intravenous/*administration & dosage/adverse effects
Bronchodilator Agents/therapeutic use
Dexamethasone/therapeutic use
Emulsions/chemistry
Epinephrine/therapeutic use
Glucocorticoids/therapeutic use
Humans
Injections, Intravenous
Male
Propofol/*administration & dosage/adverse effects
Anesthetics, Intravenous
Bronchodilator Agents
Emulsions
Glucocorticoids
Propofol
Dexamethasone
Epinephrine

Reference

1. Harper NJ, Dixon T, Dugué P, Edgar DM, Fay A, Gooi HC, Herriot R, Hopkins P, Hunter JM, Mirakian R, et al. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia. 2009. 64:199–211.

2. Mertes PM, Laxenaire MC, Alla F. Groupe d'Etudes des Réactions Anaphylactoïdes Peranesthésiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003. 99:536–545.

3. Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL. Life-threatening anaphylactoid reactions to propofol (Diprivan). Anesthesiology. 1992. 77:275–280.

4. McHale SP, Konieczko K. Anaphylactoid reaction to propofol. Anaesthesia. 1992. 47:864–865.

5. Ducart AR, Watremez C, Louagie YA, Collard EL, Broka SM, Joucken KL. Propofol-induced anaphylactoid reaction during anesthesia for cardiac surgery. J Cardiothorac Vasc Anesth. 2000. 14:200–201.

6. de Leon-Casasola OA, Weiss A, Lema MJ. Anaphylaxis due to propofol. Anesthesiology. 1992. 77:384–386.

7. Krøigaard M, Garvey LH, Menné T, Husum B. Allergic reactions in anaesthesia: are suspected causes confirmed on subsequent testing? Br J Anaesth. 2005. 95:468–471.

8. Jung JA, Choi BM, Cho SH, Choe SM, Ghim JL, Lee HM, Roh YJ, Noh GJ. Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. Br J Anaesth. 2010. 104:563–576.

9. Mertes PM, Laxenaire MC. Allergic reactions occurring during anesthesia. Eur J Anaesthesiol. 2002. 19:240–262.

10. Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg. 2003. 97:1381–1395.

11. Joint Task Force on Practice Parameters. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005. 115:S483–S523.

12. Szebeni J. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv. 2005. 2:443–449.

13. Moghimi SM, Hunter AC, Dadswell CM, Savay S, Alving CR, Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta. 2004. 1689:103–113.